UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorpor ...

World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System, demonstrating system adoption across multiple case types ATLANTA and HINGHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Emory Healthcare has successfully completed robotic peripheral endovascular procedures — minimally invasive treatments for certain vascular conditions — using Microbot Med ...

Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, which is already garnering medical and industry attention, today announ ...

Core Insights - Microbot Medical Inc. is preparing for the full market release of its LIBERTY Endovascular Robotic System in April 2026, following a successful limited market release that began in late 2025 [3][4] - The company will present at the Roth Annual Growth Conference on March 23, 2026, where CEO Harel Gadot will discuss recent achievements and the unique aspects of the LIBERTY system [1][2] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY system is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [3][4] Market Strategy - The company aims to leverage the Roth conference to showcase its commercial momentum and growth story to a diverse audience, which is expected to support its current position and future growth [3] - The LIBERTY system addresses critical unmet healthcare needs, including physician safety and staffing issues, which are increasingly important in the medical field [3]

Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market ReleaseHINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026. This marks the first ...

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare ProvidersHINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association’s (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for health care pr ...

Core Insights - Microbot Medical Inc. is not experiencing any business disruption due to current geopolitical events, prioritizing employee safety and operational continuity [1][4] - The company has shifted its commercial focus to the U.S. market following FDA clearance of the LIBERTY Endovascular Robotic System, ensuring reliable distribution and service [2] - A full market release of the LIBERTY System is planned for the Society of Interventional Radiology (SIR) conference in April 2026, with efforts to enhance commercial infrastructure [3][5] Company Operations - The company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through a third-party logistics partner [2] - Additional sales representatives have been hired to expand coverage into new U.S. territories, along with a Director of Health Economics and Outcomes Research to support commercial expansion [3] Product Information - The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to reduce radiation exposure and physical strain [5][6] - The limited market release of the LIBERTY system commenced in late 2025, with the goal of deepening market adoption during the full release [5]

Microbot Medical’s recent achievement comes on the heels of its FDA 510(k) clearance for the LIBERTY system, which is designed for precision in peripheral endovascular procedures.The adoption by Tampa General Hospital is seen as a significant endorsement of LIBERTY’s value, with the hospital’s leadership emphasizing the technology’s potential to transform patient care and enhance physician safety.The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic solution in its category, aimi ...

Early Post-Clearance Momentum Signals Accelerated Hospital Adoption of Advanced RoboticsHINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking another important milestone following the Company’s recent FDA 510(k) clearance. Microbot believes that this reflects early post-clearance ...

Core Insights - Microbot Medical Inc. announced that CEO Harel Gadot will participate as a panelist at The Surgical Disruptive Technology Summit, part of SAGES NBT Innovation Weekend, from February 19-21, 2026, in Houston, TX [1] - The summit aims to foster dialogue between industry and providers on innovations in surgical technology, focusing on minimally invasive interventions [2] Company Overview - Microbot Medical is a commercial stage medical device company dedicated to transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY® Endovascular Robotic System is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [4] Product Features and Market Strategy - The LIBERTY System is designed to enhance access, safety, and clinical outcomes in vascular care, featuring remote interventions and precision navigation [2] - The company commenced limited market release of the LIBERTY system in late 2025 and plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [3] - LIBERTY's single-use, compact design aims to eliminate barriers to broader adoption of surgical robotics, positioning it as a new class of surgical robotics [3]